Harbourvest Partners’s Atara Biotherapeutics ATRA Stock Holding History

Harbourvest Partners’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-422	Closed	-$411K	–	22
2018 Q1	$411K	Hold	422	–	–	0.44%	16
2017 Q4	$191K	Hold	422	–	–	0.15%	21
2017 Q3	$174K	Hold	422	–	–	0.11%	20
2017 Q2	$148K	Hold	422	–	–	0.06%	22
2017 Q1	$217K	Hold	422	–	–	0.12%	18
2016 Q4	$150K	Hold	422	–	–	0.09%	14
2016 Q3	$226K	Hold	422	–	–	0.12%	9
2016 Q2	$237K	Hold	422	–	–	0.11%	19
2016 Q1	$201K	Hold	422	–	–	0.09%	20
2015 Q4	$278K	Hold	422	–	–	0.1%	19
2015 Q3	$331K	Buy	+422	New	+$515K	0.15%	17

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Harbourvest Partners's ATRA Position: Q2 2018 in Review

Harbourvest Partners sold out of Atara Biotherapeutics (ATRA) in Q2 2018, closing a stake of 422 shares — an estimated $411K sold.

Harbourvest Partners first reported a position in ATRA in Q3 2015 and held it in 11 quarters. The position peaked at $411K in Q1 2018. 124 funds tracked by Wall St. Rank hold ATRA as of Q2 2018.

Harbourvest Partners reported no remaining Atara Biotherapeutics position as of Q2 2018 after selling out during the quarter.
Harbourvest Partners sold 422 Atara Biotherapeutics shares in Q2 2018, an estimated $411K.
Harbourvest Partners first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 11 quarters.
Harbourvest Partners's Atara Biotherapeutics position peaked at $411K in Q1 2018.
124 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2018.

Based on Harbourvest Partners's 13F filing for Q2 2018, filed 14 Aug 2018.